Medtronic (NYSE: MDT) announced today that it received FDA approval for the expanded redo-TAVR indication of its Evolut system.

A global review of transcatheter-valve implants done in failed bioprosthetics hints that best outcomes have less to do with the TAVR procedure and more with the original valve surgery.

Background: Transcatheter aortic valve replacement (TAVR) is increasingly performed in younger, low surgical risk patients. This NOTION-2 study reports mid-term outcomes in low-risk patients aged ...

Device durability for transcatheter aortic valve replacement (TAVR) devices remains topical for patients, payers and regulators, but the standard measure of 10-year data were difficult to obtain for ...

Pulmonary hypertension patients who undergo transcatheter aortic valve replacement are at a higher risk for mortality than those without pulmonary hypertension, according to a recent study.

Trinity Health System has been designated as a Transcatheter Aortic Valve Replacement, or TAVR, Center of Excellence. This prestigious recognition is awarded by ...

TAVR Program Coordinator Jessica Duke said of the procedure, “It's requiring only an overnight stay in the hospital, more for ...

He will present outcomes from the TAVI-1 trial of the Optimum TAVI System™ at the world-leading Transcatheter Cardiovascular Therapeutics (TCT) Conference in the “Innovations in TAVR Systems ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in ...